Leah Cann
Stock Analyst at Brookline Capital
(0.22)
# 3,675
Out of 4,667 analysts
16
Total ratings
33.33%
Success rate
-23.82%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Leah Cann
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MEIP MEI Pharma | Maintains: Buy | $80 | $2.80 | +2,757.14% | 2 | May 23, 2023 | |
| CRBU Caribou Biosciences | Initiates: Buy | $19 | $1.96 | +869.39% | 1 | Feb 14, 2022 | |
| CCCC C4 Therapeutics | Initiates: Buy | $54 | $4.05 | +1,233.33% | 1 | Jun 24, 2021 | |
| AGIO Agios Pharmaceuticals | Assumes: Perform | n/a | $54.62 | - | 4 | Feb 20, 2019 | |
| EXEL Exelixis | Upgrades: Outperform | n/a | $34.65 | - | 2 | Feb 27, 2018 | |
| NTLA Intellia Therapeutics | Initiates: Perform | n/a | $13.12 | - | 1 | Jul 18, 2017 | |
| EDIT Editas Medicine | Initiates: Perform | n/a | $2.41 | - | 1 | Jul 18, 2017 | |
| CRSP CRISPR Therapeutics AG | Initiates: Perform | n/a | $47.26 | - | 1 | Jul 18, 2017 | |
| VSTM Verastem | Initiates: Outperform | $72 | $3.79 | +1,799.74% | 3 | Apr 13, 2017 |
MEI Pharma
May 23, 2023
Maintains: Buy
Price Target: $80
Current: $2.80
Upside: +2,757.14%
Caribou Biosciences
Feb 14, 2022
Initiates: Buy
Price Target: $19
Current: $1.96
Upside: +869.39%
C4 Therapeutics
Jun 24, 2021
Initiates: Buy
Price Target: $54
Current: $4.05
Upside: +1,233.33%
Agios Pharmaceuticals
Feb 20, 2019
Assumes: Perform
Price Target: n/a
Current: $54.62
Upside: -
Exelixis
Feb 27, 2018
Upgrades: Outperform
Price Target: n/a
Current: $34.65
Upside: -
Intellia Therapeutics
Jul 18, 2017
Initiates: Perform
Price Target: n/a
Current: $13.12
Upside: -
Editas Medicine
Jul 18, 2017
Initiates: Perform
Price Target: n/a
Current: $2.41
Upside: -
CRISPR Therapeutics AG
Jul 18, 2017
Initiates: Perform
Price Target: n/a
Current: $47.26
Upside: -
Verastem
Apr 13, 2017
Initiates: Outperform
Price Target: $72
Current: $3.79
Upside: +1,799.74%